Literature DB >> 10370678

Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma.

E E Tzoracoleftherakis1, J D Spiliotis, T Kyriakopoulou, S K Kakkos.   

Abstract

BACKGROUND/AIMS: To compare intra-arterial (regional) hepatic chemotherapy with doxorubicin, to the systemic (intravenous) one in patients with non-resectable (Stage IVA) hepatocellular carcinoma.
METHODOLOGY: Seventy-two patients with inoperable hepatocellular carcinoma were randomized to receive doxorubicin 50 mg/m2 as a bolus infusion either via an implantable intra-arterial catheter (Group A) or as systemic chemotherapy (Group B) every 21-28 days.
RESULTS: Patients of Group A had a higher rate of objective and subjective remissions and Karnofsky performance status improvement in comparison to Group B. The mean survival was 7 months (range: 2-16) for Group A and 6.5 months (range: 1-13) for Group B, but this difference was not statistically significant. The quality of life remained at an acceptable level until death in both groups.
CONCLUSIONS: A slight but not statistically significant superiority of intra-arterial chemotherapy against the systemic one is concluded.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10370678

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  10 in total

Review 1.  Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy.

Authors:  Tatsuya Yamashita
Journal:  Clin Drug Investig       Date:  2012-08-08       Impact factor: 2.859

2.  Current chemotherapies for advanced hepatocellular carcinoma.

Authors:  Kazuhiro Nouso
Journal:  Clin J Gastroenterol       Date:  2013-02-06

3.  Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (Review).

Authors:  Hiroki Ueda; Hiroko Fukuchi; Chigusa Tanaka
Journal:  Oncol Lett       Date:  2011-11-02       Impact factor: 2.967

Review 4.  Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; Flora Hau-Fung Tsang; John Wong
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

5.  Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study.

Authors:  Zheng-Gang Ren; Zhi-Ying Lin; Jing-Lin Xia; Sheng-Long Ye; Zeng-Chen Ma; Qing-Hai Ye; Lun-Xiu Qin; Zhi-Quan Wu; Jia Fan; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

6.  A case of hepatocellular carcinoma with pulmonary metastases treated successfully with a combination of repeated hepatic arterial infusion epirubicin and Cisplatin chemotherapy and systemic low-dose infusion of 5-Fluorouracil.

Authors:  Yun-Jung Oh; Young-Min Park; Bo-Hyun Kim; Mi-Jin Kim; Jun-Hyung Cho; Chi-Woon Cha; Sang-Jong Park; Jae-Woo Yeon
Journal:  Gut Liver       Date:  2009-12-31       Impact factor: 4.519

7.  Surgery combined with controlled-release doxorubicin silk films as a treatment strategy in an orthotopic neuroblastoma mouse model.

Authors:  B Chiu; J Coburn; M Pilichowska; C Holcroft; F P Seib; A Charest; D L Kaplan
Journal:  Br J Cancer       Date:  2014-06-12       Impact factor: 7.640

8.  Phase II study to topotecan and cisplatin in advanced hepatocellular carcinoma.

Authors:  Ga Young Lee; Bong-Seog Kim; Yeoung Tae Seo; Seong Ho Choi; Hye Jin Kim; Dong Seog Choi; Ji Young Ko; Soo Hyun Yang; Jong Hoon Byun
Journal:  Korean J Intern Med       Date:  2003-06       Impact factor: 2.884

9.  Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan.

Authors:  Hiroki Nishikawa; Yukio Osaki; Ryuichi Kita; Toru Kimura
Journal:  Cancers (Basel)       Date:  2012-02-21       Impact factor: 6.639

10.  Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma.

Authors:  Atsushi Hagihara; Masafumi Ikeda; Hideki Ueno; Chigusa Morizane; Shunsuke Kondo; Kohei Nakachi; Shuichi Mitsunaga; Satoshi Shimizu; Yasushi Kojima; Eiichiro Suzuki; Kazuhiro Katayama; Kazuho Imanaka; Chie Tamai; Yoshitaka Inaba; Yozo Sato; Mina Kato; Takuji Okusaka
Journal:  Cancer Sci       Date:  2014-02-18       Impact factor: 6.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.